Imagene was founded with a clear mission to leverage AI to profile, in real time, a broad range of biomarkers from biopsy images. By doing so, the company aims to overcome economical, logistical, and technological barriers to reach the full potential of precision medicine for all cancer patients.
Imagene's technology classifies patterns that cannot be seen by the human eye, evolving genomics, proteomics, and spatial insights, resulting in a fast and accurate molecular profiling. The company's technology also enables better stratification of patients for clinical trials and the discovery of novel targets for new drugs.

Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide. It was selected for The Marker's Most Promising Start-Ups for 2022, and named Oncology Innovation of the Year by the BioTech Breakthrough Awards.

Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is working to revolutionize molecular screening for both clinical practice and research.